Comparison of 6 automated assays for total and free prostate-specific antigen with special reference to their reactivity toward the WHO 96/670 reference preparation.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Clinical Chemistry

• Publication date

  2006-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1373/CLINCHEM.2006.069039PMID 16762996
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Prostate-specific antigen: bias and molarity of commercial assays for PSA in use in England

  2006cited by this paper
• Standardization of prostate-specific antigen (PSA) assays: can interchangeability of PSA measurements be improved?

  2006cited by this paper
• Interchangeability of measurements of total and free prostate-specific antigen in serum with 5 frequently used assay combinations: an update.

  2006cited by this paper
• Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial.

  2005cited by this paper
• Strategies combining total and percent free prostate specific antigen for detecting prostate cancer: a prospective evaluation.

  2002cited by this paper
• Comparative evaluation of total PSA, free/total PSA, and complexed PSA in prostate cancer detection.

  2002cited by this paper
• Discordant performance of assays for free and total prostate‐specific antigen in relation to the early detection of prostate cancer

  2001cited by this paper
• Prostate specific antigen: biology, biochemistry and available commercial assays

  2001cited by this paper
• The clinical impact of different assays for prostate specific antigen

  2000cited by this paper
• A comparison of six commercial assays for total and free prostate specific antigen (PSA): the predictive value of the ratio of free to total PSA

  2000cited by this paper
• Reference reagents for prostate-specific antigen (PSA): establishment of the first international standards for free PSA and PSA (90:10)

  2000cited by this paper
• WHO first international standards for prostate-specific antigen: the beginning of the end for assay discrepancies?

  2000cited by this paper
• Analytical characteristics of seminal fluid PSA differ from those of serum PSA.

  1998cited by this paper
• Reference material for PSA: the IFCC standardization study. International Federation of Clinical Chemistry.

  1998cited by this paper
• Percent free prostate-specific antigen in assessing the probability of prostate cancer under optimal analytical conditions.

  1998cited by this paper
• Five PSA methods compared by assaying samples with defined PSA ratios.

  1997cited by this paper
• Large discrepancy between prostate-specific antigen results from different assays during longitudinal follow-up of a prostate cancer patient.

  1996cited by this paper
• Prospective Evaluation Plan for Randomised Trials of Prostate Cancer Screening

  1996cited by this paper
• Prostate-specific antigen: biochemistry, analytical methods, and clinical application.

  1993cited by this paper
• Quality control in clinical chemistry. Part 2. Assessment of analytical methods for routine use.

  1976cited by this paper

• Comparison Between a New PSA Assay With the Well‐Established Beckman Coulter Immunoassay: A Preliminary Report

  2025influential citation
• Inflammation-immune-nutrition biomarkers and PSA variability: A population-based study on the clinical potential of the CALLY index.

  2025cites this paper
• Interassay Variability and Clinical Implications of Five Different Prostate-specific Antigen Assays

  2024cites this paper
• The Impact of Prostate-Specific Antigen Screening on Prostate Cancer Incidence and Mortality in China: 13-Year Prospective Population-Based Cohort Study

  2024cites this paper
• Prostate-Specific Antigen as an Ultrasensitive Biomarker for Patients with Early Recurrent Prostate Cancer: How Low Shall We Go? A Systematic Review

  2024cites this paper
• Consistency and diagnostic accuracy of 4 assays in the detection of the total and free prostate-specific antigen

  2023cites this paper
• Analytical and Clinical Assessment of Prostate Specific Antigen Using an HISCL-5000 Chemiluminescence Immunoassay

  2022cites this paper
• Comparison of Three Assays for Total and Free PSA Using Hybritech and WHO Calibrations

  2021cites this paper
• Age-Adjusted Reference Values for Prostate Specific Antigen - A Systematic Review and Meta-Analysis.

  2021cites this paper
• Verification of Harmonization of Serum Total and Free Prostate-Specific Antigen (PSA) Measurements and Implications for Medical Decisions.

  2020cites this paper
• Internal Validation and Correlation of 2 Different Prostate Specific Antigen Assays for Prostate Cancer Screening in Community Based Men.

  2020cites this paper
• Clinical interpretation of prostate-specific antigen values: Type of applied cut-off value exceeds methods bias as the major source of variation

  2019cites this paper
• Prostate cancer screening: guidelines review and laboratory issues

  2019cites this paper
• Systematic Differences Between Total and Free Prostate-Specific Antigen Immunoassays: Comparison Using Passing and Bablok Regression

  2019cites this paper
• Continued provision of WHO International Standards for total and free PSA: Content and commutability of replacement preparations.

  2019cites this paper
• Development and Evaluation of an Immunoglobulin Y-Based ELISA for Measuring Prostate Specific Antigen in Human Serum

  2019cites this paper
• Multicenter Comparison of Four Automated Immunoassay Analyzers for Prostate Specific Antigen

  2019cites this paper
• Comparison of self-reported female condom failure and biomarker-confirmed semen exposure.

  2019cites this paper
• Discordant prostate specific antigen test results despite WHO assay standardization

  2018cites this paper
• A Novel Calculator for Estimating Prostate Volume in Daily Urology Services.

  2018cites this paper
• Revisiting prostate specific antigen density ( PSAD ) : a prospective analysis in predicting the histology of prostate biopsy

  2018cites this paper
• Serum carotenoid and retinol levels in African-Caribbean Tobagonian men with high prostate cancer risk in comparison with African-American men

  2017cites this paper
• A Black Swan in clinical laboratory practice: the analytical error due to interferences in immunoassay methods

  2017cites this paper
• Clinical impact of prostate specific antigen (PSA) inter-assay variability on management of prostate cancer.

  2016cites this paper
• Molecular Form Differences Between Prostate-Specific Antigen (PSA) Standards Create Quantitative Discordances in PSA ELISA Measurements

  2016cites this paper
• Determining the Ratio of Two Types of Prostate Specific Antigens with Biochips and Gold Nanoparticles for Accurate Prostate Cancer Diagnosis

  2016cites this paper
• Chancen und Risiken von e-Health in der Labormedizin

  2016cites this paper
• Studying Biomolecular Structures and Their Interaction Using Atomic Force Microscopy

  2015cites this paper
• A three-arm scaffold carrying affinity molecules for multiplex recognition imaging by atomic force microscopy: the synthesis, attachment to silicon tips, and detection of proteins.

  2015cites this paper
• Immunoassay for the discrimination of free prostate-specific antigen (fPSA) forms with internal cleavages at Lys 145 or Lys 146 from fPSA without internal cleavages at Lys 145 or Lys 146

  2014cites this paper
• Analytical performance of a new one-step quantitative prostate-specific antigen assay, the FREND™ PSA Plus

  2014influential citation
• Prostate specific antigen. Current clinical application and future prospects.

  2014cites this paper
• Assessing the necessity of including a crossover period with dual reporting when changing total prostate-specific antigen methods.

  2014cites this paper
• Antigène Prostatique Spécifique (PSA) total et libre

  2014cites this paper
• Analytical performance of the VITROS® Immunodiagnostic Products total PSA II and free PSA assays.

  2014cites this paper
• Ethnicity Is an Independent Determinant of Age-Specific PSA Level: Findings from a Multiethnic Asian Setting

  2014cites this paper
• Variability of assay methods for total and free PSA after WHO standardization

  2014cites this paper
• An Inexpensive, Fast and Sensitive Quantitative Lateral Flow Magneto-Immunoassay for Total Prostate Specific Antigen

  2014cites this paper
• Current clinical application and future prospects

  2014cites this paper
• Mass spectrometry measurements of prostate-specific antigen (PSA) peptides derived from immune-extracted PSA provide a potential strategy for harmonizing immunoassay differences.

  2014cites this paper
• Prospective multicenter evaluation of the Beckman Coulter Prostate Health Index using WHO calibration.

  2013cites this paper
• On-chip screening for prostate cancer: an EIS microfluidic platform for contemporary detection of free and total PSA.

  2013cites this paper
• Discovery and validation of prostate cancer biomarkers

  2013cites this paper
• Aberrant results observed with four immuno-assays for total and free prostate-specific antigen (PSA) determination: a case-report

  2012cites this paper
• Standardization of assay methods reduces variability of total PSA measurements: an Irish study

  2012cites this paper
• Prostate cancer screening

  2012cites this paper
• Effect of Age, Family History of Prostate Cancer, Prostate Enlargement and Seasonality on PSA Levels in a Contemporary Cohort of Healthy Italian Subjects

  2011cites this paper
• Reproductive toxicity parameters and biological monitoring in occupationally and environmentally boron-exposed persons in Bandırma, Turkey

  2011cites this paper
• Rational Approach to Implementation of PCA 3 into Clinical Care

  2011cites this paper
• Is the WHO 90:10 prostate-specific antigen (PSA) first international reference standard really 90% α1-antichymotrypsin-bound PSA and 10% free PSA?

  2011cites this paper
• Immunoassay for the discrimination of free prostate-specific antigen (fPSA) forms with internal cleavages at Lys(₁₄₅) or Lys(₁₄₆) from fPSA without internal cleavages at Lys(₁₄₅) or Lys(₁₄₆).

  2011cites this paper
• Is there an optimal prostate-specific antigen threshold for prostate biopsy?

  2011cites this paper
• Avoiding pitfalls in applying prediction models, as illustrated by the example of prostate cancer diagnosis.

  2011cites this paper
• Metrological traceability in clinical biochemistry

  2011cites this paper
• Between-method differences in prostate-specific antigen assays affect prostate cancer risk prediction by nomograms.

  2011cites this paper
• Prostate cancer screening: clinical impact of WHO calibration of Beckman Coulter Access® prostate-specific antigen assays

  2010cites this paper
• Complexed and total PSA in patients with benign prostatic hyperplasia and prostate cancer

  2010cites this paper
• Prostate-specific antigen-based screening for prostate cancer in the third millennium: Useful or hype?

  2009cites this paper
• 20–25% Lower Concentrations of Total and Free Prostate-Specific Antigen (PSA) after Calibration of PSA Assays to the WHO Reference Materials – Analysis of 1098 Patients in Four Centers

  2009cites this paper
• Rational approach to implementation of prostate cancer antigen 3 into clinical care

  2009cites this paper
• A systematic review of the diagnostic accuracy of prostate specific antigen

  2009cites this paper
• Discordant total and free prostate-specific antigen (PSA) assays: does calibration with WHO reference materials diminish the problem?

  2009cites this paper
• 20-25% lower concentrations of total and free prostate-specific antigen (PSA) after calibration of PSA assays to the WHO reference materials--analysis of 1098 patients in four centers.

  2009cites this paper
• The Clinical Impact of who Standardization of PSA Assays

  2008influential citation
• Evaluation of immunoexpression and MDR1 promoter methylation levels in prostatic tissue samples

  2008cites this paper
• Clinical implications of introducing a new PSA assay

  2008cites this paper
• Comparison of Hybritech and WHO standardization applied to access Hybritech total PSA assay on UniCel ®

  2008cites this paper
• Toward metrological traceability in the determination of prostate-specific antigen (PSA): calibrating Beckman Coulter Hybritech Access PSA assays to WHO standards compared with the traditional Hybritech standards

  2008cites this paper
• Clinical impact of new prostate-specific antigen WHO standardization on biopsy rates and cancer detection.

  2008influential citation
• National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers.

  2008cites this paper
• Artificial neural network (ANN) velocity better identifies benign prostatic hyperplasia but not prostate cancer compared with PSA velocity

  2008cites this paper
• Why determine only the total prostate-specific antigen, if the free-to-total ratio contains the information?

  2008cites this paper
• Intermethod differences in results for total PSA, free PSA, and percentage of free PSA.

  2008cites this paper
• PSA and new biomarkers within multivariate models to improve early detection of prostate cancer.

  2007cites this paper
• Age-Specific Reference Ranges for Prostate-Specific Antigen as a Marker for Prostate Cancer

  2007cites this paper
• Monoclonal antibody selection for interleukin-4 quantification using suspension arrays and forward-phase protein microarrays.

  2007cites this paper
• Different prostate‐specific antigen assays give different results on the same blood sample: an obstacle to recommending uniform limits for prostate biopsies

  2007cites this paper
• Improving the comparability of immunoassays for prostate-specific antigen (PSA): progress and problems.

  2007cites this paper
• Analytische und klinische Validierung der fünf meistbenutzten Testkombinationen zur Bestimmung des totalen und freien prostata-spezifischen Antigens: Vergleichsmessungen an 798 Seren von Patienten mit Prostatakarzinom und benigner Prostatahyperplasie

  2007cites this paper
• Variations in assay protocol for the Dako cystatin C method may change patient results by 50% without changing the results for controls

  2006cites this paper